Science Explorer Back to mapMap
Institution · Xencor (United States)

Most cited papers from Xencor (United States)

What are the most cited papers from Xencor (United States)?

The most cited paper from Xencor (United States) is "Engineered antibody Fc variants with enhanced effector function" (Greg A. Lazar, Wei Dang, Sher Karki et al., 2006), with 804 citations. Next come "Enhanced antibody half-life improves in vivo activity" (664) and "JNK and Tumor Necrosis Factor-α Mediate Free Fatty Acid-induced Insulin Resistance in 3T3-L1 Adipocytes" (405).

Showing 50 of 60 papers. Every paper with more than 52 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Engineered antibody Fc variants with enhanced effector function Greg A. Lazar, Wei Dang, Sher Karki et al. · Proceedings of the National Academy of Sciences Open access 6 Mar 2006 804
2 Enhanced antibody half-life improves in vivo activity Jonathan Zalevsky, Aaron K. Chamberlain, Holly M. Horton et al. · Nature Biotechnology Open access 17 Jan 2010 664
3 JNK and Tumor Necrosis Factor-α Mediate Free Fatty Acid-induced Insulin Resistance in 3T3-L1 Adipocytes Matthew T. Nguyen, Hiroaki Satoh, Svetlana Favelyukis et al. · Journal of Biological Chemistry Open access 6 Aug 2005 405
4 Characterizing biological products and assessing comparability following manufacturing changes Arthur J. Chirino, Anthony R. Mire‐Sluis · Nature Biotechnology Nov 2004 364
5 Blocking Soluble Tumor Necrosis Factor Signaling with Dominant-Negative Tumor Necrosis Factor Inhibitor Attenuates Loss of Dopaminergic Neurons in Models of Parkinson's Disease Melissa K. McCoy, Terina N. Martinez, Kelly A. Ruhn et al. · Journal of Neuroscience Open access 13 Sep 2006 362
6 Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells John O. Richards, Sher Karki, Greg A. Lazar et al. · Molecular Cancer Therapeutics Aug 2008 311
7 Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia Holly M. Horton, Matthew J. Bernett, Erik Pong et al. · Cancer Research 30 Sep 2008 272
8 Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions Gregory L. Moore, Hsing Chen, Sher Karki et al. · mAbs Open access Mar 2010 264
9 Inactivation of TNF Signaling by Rationally Designed Dominant-Negative TNF Variants Paul M. Steed et al. · Science 25 Sep 2003 261
10 Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination Roberta Brambilla, Jessica Jopek Ashbaugh, Roberta Magliozzi et al. · Brain Open access 29 Aug 2011 215
11 Rational design and engineering of therapeutic proteins Shannon A. Marshall, Greg A. Lazar, Arthur J. Chirino et al. · Drug Discovery Today Mar 2003 204
12 Minimizing the immunogenicity of protein therapeutics Arthur J. Chirino, Marylouise Ary, Shannon A. Marshall · Drug Discovery Today 2004 178
13 Oligodendroglial TNFR2 Mediates Membrane TNF-Dependent Repair in Experimental Autoimmune Encephalomyelitis by Promoting Oligodendrocyte Differentiation and Remyelination Pernille M. Madsen, Dario Motti, Shaffiat Karmally et al. · Journal of Neuroscience Open access 4 May 2016 162
14 Dominant-Negative Inhibitors of Soluble TNF Attenuate Experimental Arthritis without Suppressing Innate Immunity to Infection Jonathan Zalevsky, Thomas Sécher, Sergei A. Ezhevsky et al. · The Journal of Immunology Aug 2007 161
15 Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies Seung Y. Chu, Igor Voštiar, Sher Karki et al. · Molecular Immunology 13 Aug 2008 158
16 Antibody-Mediated Coengagement of FcγRIIb and B Cell Receptor Complex Suppresses Humoral Immunity in Systemic Lupus Erythematosus Holly M. Horton, Seung Y. Chu, Elizabeth Ortiz et al. · The Journal of Immunology Mar 2011 145
17 Soluble TNF Mediates the Transition from Pulmonary Inflammation to Fibrosis Nikos Oikonomou, Vaggelis Harokopos, Jonathan Zalevsky et al. · PLoS ONE Open access 26 Dec 2006 136
18 Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective John R. Desjarlais, Greg A. Lazar, Eugene A. Zhukovsky et al. · Drug Discovery Today Nov 2007 134
19 Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell–recruiting Antibody Optimized for Cytotoxicity and Cytokine Release Christina L. Zuch de Zafra, Flordeliza Fajardo, Wendy W. H. Zhong et al. · Clinical Cancer Research 28 Mar 2019 133
20 Cation−π Interactions: An Energy Decomposition Analysis and Its Implication in δ-Opioid Receptor−Ligand Binding Yirong Mo, Govindan Subramanian, Jiali Gao et al. · Journal of the American Chemical Society 5 Apr 2002 132
21 Combining computational and experimental screening for rapid optimization of protein properties Robert J. Hayes, Jörg Bentzien, Marylouise Ary et al. · Proceedings of the National Academy of Sciences Open access 21 Nov 2002 130
22 CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain–engineered monoclonal antibody Farrukh Tauseef Awan, Rosa Lapalombella, Rossana Trotta et al. · Blood Open access 3 Dec 2009 130
23 Hippocampal TNFα Signaling Contributes to Seizure Generation in an Infection-Induced Mouse Model of Limbic Epilepsy Dipan C. Patel, Glenna J. Wallis, E. Jill Dahle et al. · eNeuro Open access Mar 2017 112
24 Degrading chloroplast mRNA: the role of polyadenylation Robert J. Hayes, Jörg Kudla, Wilhelm Gruissem · Trends in Biochemical Sciences Review May 1999 112
25 Therapeutic inhibition of soluble brain TNF promotes remyelination by increasing myelin phagocytosis by microglia Maria Karamita, Christopher J. Barnum, Wiebke Möbius et al. · JCI Insight Open access 19 Apr 2017 111
26 A molecular immunology approach to antibody humanization and functional optimization Greg A. Lazar, John R. Desjarlais, Jonathan M. Jacinto et al. · Molecular Immunology 2 Nov 2006 110
27 Thoroughly sampling sequence space: Large‐scale protein design of structural ensembles Stefan Larson, Jeremy L. England, John R. Desjarlais et al. · Protein Science Open access 20 Nov 2002 109
28 Systemically administered anti-TNF therapy ameliorates functional outcomes after focal cerebral ischemia Bettina Hjelm Clausen, Matilda Degn, Nellie Anne Martin et al. · Journal of Neuroinflammation Open access Dec 2014 106
29 A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens Gregory L. Moore, Cristina Bautista, Erik Pong et al. · mAbs Open access Nov 2011 105
30 The impact of Fc engineering on an anti-CD19 antibody: increased Fcγ receptor affinity enhances B-cell clearing in nonhuman primates Jonathan Zalevsky, Irene Leung, Sher Karki et al. · Blood 25 Dec 2008 101
31 Clinical link between MHC class II haplotype and interferon-beta (IFN-β) immunogenicity Maria D.F.S. Barbosa, Jost Vielmetter, Seung Y. Chu et al. · Clinical Immunology 3 Nov 2005 100
32 Transmembrane tumour necrosis factor is neuroprotective and regulates experimental autoimmune encephalomyelitis via neuronal nuclear factor-κB Era Taoufik, Vivian Tseveleki, Seung Y. Chu et al. · Brain 29 Aug 2011 95
33 Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody Seung Y. Chu, Holly M. Horton, Erik Pong et al. · Journal of Allergy and Clinical Immunology 16 Jan 2012 95
34 DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3 Rahul S. Bhansali et al. · Journal of Clinical Investigation Open access 3 Jan 2021 92
35 The TNF superfamily in 2009: new pathways, new indications, and new drugs Malu Gámez Tansey, David E. Szymkowski · Drug Discovery Today 17 Oct 2009 89
36 Transmembrane TNF‐α is sufficient for articular inflammation and hypernociception in a mouse model of gout Flávio Almeida Amaral, Leandro F.S. Bastos, Thiago Henrique Oliveira et al. · European Journal of Immunology Open access 9 Oct 2015 82
37 Computational stabilization of human growth hormone Anton V. Filikov, Robert J. Hayes, Peizhi Luo et al. · Protein Science Open access Jun 2002 77
38 Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies Holly M. Horton, Matthew J. Bernett, Matthias Peipp et al. · Blood Open access 9 Jul 2010 74
39 Central but not systemic administration of XPro1595 is therapeutic following moderate spinal cord injury in mice Hans Gram Novrup, Valerie C. Bracchi-Ricard, Ditte Gry Ellman et al. · Journal of Neuroinflammation Open access 9 Sep 2014 73
40 A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats Gregory L. Moore, Matthew J. Bernett, Rumana Rashid et al. · Methods Open access 23 Oct 2018 72
41 Harnessing Fc receptor biology in the design of therapeutic antibodies Peter Sondermann, David E. Szymkowski · Current Opinion in Immunology Review 30 Mar 2016 72
42 Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial Cory A. Perugino, Zachary Scott Wallace, Debra Jeske Zack et al. · The Lancet Rheumatology 24 Jul 2023 70
43 Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study Farhad Ravandi, Asad Bashey, Wendy Stock et al. · Blood 4 Nov 2020 70
44 Redirected T Cell Cytotoxicity in Cancer Therapy Raphael Clynes, John R. Desjarlais · Annual Review of Medicine Review 31 Oct 2018 70
45 Dissection of specific binding of HIV-1 Gag to the 'packaging signal' in viral RNA Mauricio Comas‐García, Siddhartha AK Datta, Laura E. Baker et al. · eLife Open access 20 Jul 2017 69
46 Neutralization of Membrane TNF, but Not Soluble TNF, Is Crucial for the Treatment of Experimental Colitis Clémentine Perrier, Gert D. Hertogh, Jonathan Cremer et al. · Inflammatory Bowel Diseases Open access 30 May 2012 68
47 Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15 Lazar N. Vujanovic, David E. Szymkowski, Sean M. Alber et al. · Blood Open access 30 Apr 2010 67
48 Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co‐Expression Patterns: A Double‐Blind , Randomized, Placebo‐Controlled , Phase 2 Trial Joan T. Merrill, Joel M. Guthridge, Miles C. Smith et al. · Arthritis & Rheumatology 17 Jul 2023 66
49 A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL Jennifer Ann Woyach, Farrukh Tauseef Awan, Ian W. Flinn et al. · Blood Open access 10 Oct 2014 66
50 Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Anti‐CD19 Antibody That Coengages B Cell Antigen Receptor Complex and Fcγ Receptor IIb Inhibitory Receptor Seung Y. Chu, Karen C. Yeter, Roshan Kotha et al. · Arthritis & Rheumatology 24 Dec 2013 63

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.